Abbisko Cayman (HKSE:02256) Scaled Net Operating Assets : 0.02 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Abbisko Cayman Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Abbisko Cayman's operating assets for the quarter that ended in Dec. 2023 was HK$156.38 Mil. Abbisko Cayman's operating liabilities for the quarter that ended in Dec. 2023 was HK$107.80 Mil. Abbisko Cayman's Total Assets for the quarter that ended in Jun. 2023 was HK$2,568.01 Mil. Therefore, Abbisko Cayman's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2023 was 0.02.

Abbisko Cayman Scaled Net Operating Assets Historical Data

The historical data trend for Abbisko Cayman's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abbisko Cayman Scaled Net Operating Assets Chart

Abbisko Cayman Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Scaled Net Operating Assets

-2.30

-5.72

0.07

0.01

0.02

Abbisko Cayman Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Scaled Net Operating Assets	Get a 7-Day Free Trial			-	0.01	0.01	0.03	0.02

Competitive Comparison of Abbisko Cayman's Scaled Net Operating Assets

For the Biotechnology subindustry, Abbisko Cayman's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abbisko Cayman's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abbisko Cayman's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Abbisko Cayman's Scaled Net Operating Assets falls into.

Abbisko Cayman Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Abbisko Cayman's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2023 )
=	(Operating Assets (A: Dec. 2023 )	-	Operating Liabilities (A: Dec. 2023 ))	/	Total Assets (A: Dec. 2022 )
=	(156.381	-	107.799)	/	2780.116
=	0.02

where

	Operating Assets		(A: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	2313.76	-	2157.379
=	156.381

	Operating Liabilities		(A: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	146.873	-	27.469	-	11.605
=	107.799

Abbisko Cayman's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Dec. 2023 )
=	(Operating Assets (Q: Dec. 2023 )	-	Operating Liabilities (Q: Dec. 2023 ))	/	Total Assets (Q: Jun. 2023 )
=	(156.381	-	107.799)	/	2568.01
=	0.02

where

	Operating Assets		(Q: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	2313.76	-	2157.379
=	156.381

	Operating Liabilities		(Q: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	146.873	-	27.469	-	11.605
=	107.799

Abbisko Cayman Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Abbisko Cayman's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Abbisko Cayman (HKSE:02256) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abbisko Cayman Ltd (HKSE:02256) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

8ZD:Germany

Address

Building 3, No. 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, CHN

Website

https://www.abbisko.com

Abbisko Cayman Ltd is a investment holding company it operates through its subsidiaries which is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The company has only one business segment which is the development of innovative medicines.

Executives

Lav Asset Management (hong Kong) Limited	2102 Investment manager
Shi Yi	2201 Interest of corporation controlled by you
Xu Yao-chang	2101 Beneficial owner
Yu Hongping	2501 Other
Chen Zhui	2501 Other
Futu Trustee Limited	2301 Trustee
Temasek Holdings (private) Limited	2201 Interest of corporation controlled by you
Yu Hongping	2501 Other
Morgan Stanley	2201 Interest of corporation controlled by you
Temasek Life Sciences Private Limited
Trident Trust Company (hk) Limited	2301 Trustee
Computershare Hong Kong Trustees Limited	2301 Trustee
Morgan Stanley Investments (uk)	2201 Interest of corporation controlled by you
Morgan Stanley International Limited	2201 Interest of corporation controlled by you
Morgan Stanley International Holdings Inc.	2201 Interest of corporation controlled by you

Abbisko Cayman (HKSE:02256) Headlines

No Headlines